U ovom zadnjem broju Maxx-a nalazi se kompletan transkript sa seminara Roni Colemana u Beogradu, i verovatno si procitao tamo kad ga pitaju da li je takve misice i snagu stekao samo sa piletinom i pirincem, a on odgovara: "yes... and a few other things..."  To ti je to...

Analize na SARMs se ne vrse jer se postojecim testovima ne mogu otkriti (za sada). Realna je pretpostavka da elitni sportisti, pre svega oni sa najsofisticiranijim pripremama i sa najboljim kanalima snabdevanja "savremenom sportskom tehnologijom", vec koriste SARMs. Dakle, SARMs su po svoj prilici vec korisceni u Pekingu, a na sledecoj Olimpijadi ce biti siroko prisutni - kao sto su Olimpijadu u Atini 2004 zbog opste pojave uzimanja hormona rasta prozvali "GH Games", tako je sve izvesnije da ce sledeca Olimpijada biti "SARMs Games"  Inace, vise o SARM u novom broju Maxx-a (str. 27).

bravo MAXX ,znao sam da ces ti prvi odgovariti 
ne znam zasto me ne cudi  da se ne moze detektovati na doping testu 
za upotrebu SARM na poslednjoj olimpijadi ne znam,vrlo je verovatno doboljno je pogledati samo neke od oborenih rekorda,a na doping testovima su bili negativni 
Mada kad pogledam neke od ucesnika na poslednjoj Mr. O ,covek se prosto zapita kako napravise onako savrsena misicavaa tela( velicina,oblik,gustina,definicija,simetrija...) razumemo svi da je  tu trening,ishrana,supslementi,novij principi,AAS i ostale supstance
da li je to Sarm ili nesto drugo stvarno ne znam ??/

Analize na SARMs se ne vrse jer se postojecim testovima ne mogu otkriti (za sada). Realna je pretpostavka da elitni sportisti, pre svega oni sa najsofisticiranijim pripremama i sa najboljim kanalima snabdevanja "savremenom sportskom tehnologijom", vec koriste SARMs. Dakle, SARMs su po svoj prilici vec korisceni u Pekingu, a na sledecoj Olimpijadi ce biti siroko prisutni - kao sto su Olimpijadu u Atini 2004 zbog opste pojave uzimanja hormona rasta prozvali "GH Games", tako je sve izvesnije da ce sledeca Olimpijada biti "SARMs Games"  Inace, vise o SARM u novom broju Maxx-a (str. 27).

SARMs (Selective Androgen Receptor Modulators ) tj. selektivni modulatori androgenih recptora   

SARM je nova vrsta farmakoliskih agenata napravljena da deluje kao steroidi,ali bez nezeljenih efekata,Drugim recima,SARM deluju na ciljana tkiva
u ovom slicaju misicno tkivo,ne delujuci pri tom na druga tkiva u kojima se nalaze androgenski recptori
,otuda i naziv ``selektivni``,dakle ne steroidini agent sa anabolickom aktivnoscu koji je dizajniran da deluje kao testosteron bez remecenja libida,steriliteta,uvecanja prostate,gubitka kose itd.Oponasajuci testosteron ovaj agent dovodi do povecanja ciste misicne mase.
Inace SARM je tek u fazi ispitaivanja,i glavna namena ovakvih lekova ce biti kod bolesti i oboljenja gde je izrazen katabolizam (gubljenje misicnog tkiva )
Da li je SARM jos jedna u nizu marketinskih prevara ili ne,vreme ce pokazati,za sada SARM deluje sto kao fenomenalan proizvod narocito za sportiste i bodibilldere. 
SARM se takodje nalazi na listi zabranjenih sredstava i to u prvoj grupi (Anabolicki agensi) zajedno sa AAS.Samo ne znam kako se vrse analize za upotrebu SARM 
Za sada jedini poznat SARM je Ostarine

Evo i studije :

Background:
Cancer cachexia results in selective loss of skeletal muscle resulting in weakness, reduced physical activity and a lower quality of life. Cancer cachexia also diminishes response to chemotherapy and survival. Anabolic steroids appear to increase weight and muscle mass in cancer patients, but have the potential for masculinization in women and prostate stimulation in men. A new class of non-steroidal selective androgen receptor modulators (SARMs) is being developed for use in cancer cachexia. SARMs are designed to have predominately anabolic activity in muscle and bone with minimal androgenic effects in most other tissues. We conducted a randomized phase II proof of concept study of ostarine, the first-in-class SARM, in healthy postmenopausal women and elderly men prior to intitiating a phase II study in cancer patients. Methods: Sixty elderly men (mean age 66 years) and 60 postmenopausal women (mean age 63 years) were randomly assigned to ostarine 0.1, 0.3, 1 mg, 3 mg or placebo for three months. The primary end point was change from baseline to three months in total lean body mass (LBM) measured by dual energy x-ray absorptiometry (DXA). The key secondary end point was a stair climb functional performance test that measured speed and power exerted. Evaluations included laboratory safety assessments and additional assessments of androgenic activity including PSA, sebum production and luteinizing hormone. Results: Ostarine treatment resulted in a dose dependent increase in total LBM, with an increase of 1.4 kg compared to placebo (p<0.001) at the 3 mg dose. Increased LBM translated to an improvement in the stair climb test in both speed (+15.5% ± 12.9 faster time, p=0.006) and power (+25.5% ± 20.3 watts, p=0.005). There were no serious adverse events reported. There were no significant changes in PSA, sebum production or luteinizing hormone. Conclusions: Ostarine improves LBM and physical performance in healthy older men and women. Ostarine had no unwanted androgenic side effects. A phase II study is planned to evaluate the safety and efficacy of ostarine in patients with cancer cachexia.

Koga zanima vise:
http://endo.endojournals.org/cgi/content/abstract/en.2005-0572v1
http://jcem.endojournals.org/cgi/content/full/84/10/3459
http://jpet.aspetjournals.org/cgi/content/short/jpet.104.075424v1